Accessibility Menu
 
Microbix Biosystems logo

Microbix Biosystems

(OTC) MBXBF

Current Price$0.18
Market Cap$25.13M
Since IPO (2012)-39%
5 Year-61%
1 Year-35%
1 Month+15%

Microbix Biosystems Financials at a Glance

Market Cap

$25.13M

Revenue (TTM)

$16.76M

Net Income (TTM)

$3.79M

EPS (TTM)

$-0.02

P/E Ratio

-8.21

Dividend

$0.00

Beta (Volatility)

0.13 (Low)

Price

$0.18

Volume

5,000

Open

$0.18

Previous Close

$0.18

Daily Range

$0.18 - $0.18

52-Week Range

$0.15 - $0.31

MBXBF News

No articles available.

MBXBF: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Microbix Biosystems

Industry

Biotechnology

CEO

Cameron L. Groome

Headquarters

Mississauga, ON L4Z 1P3, CA

MBXBF Financials

Key Financial Metrics (TTM)

Gross Margin

47%

Operating Margin

-21%

Net Income Margin

-25%

Return on Equity

-16%

Return on Capital

-10%

Return on Assets

-12%

Earnings Yield

-12.18%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$25.13M

Shares Outstanding

138.55M

Volume

5.00K

Short Interest

0.00%

Avg. Volume

8.81K

Financials (TTM)

Gross Profit

$9.87M

Operating Income

$1.58M

EBITDA

$203.49K

Operating Cash Flow

$80.40K

Capital Expenditure

$798.42K

Free Cash Flow

$878.82K

Cash & ST Invst.

$12.13M

Total Debt

$8.08M

Microbix Biosystems Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$4.22M

-30.3%

Gross Profit

$1.73M

-53.8%

Gross Margin

41.09%

N/A

Market Cap

$25.13M

N/A

Market Cap/Employee

$251.34K

N/A

Employees

100

N/A

Net Income

$1.17M

-236.1%

EBITDA

$492.50K

-132.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$988.49K

-85.0%

Accounts Receivable

$3.98M

-19.5%

Inventory

$9.30M

+31.5%

Long Term Debt

$7.88M

+26.7%

Short Term Debt

$219.04K

-1.4%

Return on Assets

-11.67%

N/A

Return on Invested Capital

-10.43%

N/A

Free Cash Flow

$2.77M

-569.9%

Operating Cash Flow

$2.60M

-428.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DTCFFDefence Therapeutics Inc.
$0.43-0.98%
RVXCFResverlogix Corp.
$0.08+0.00%
PVCTProvectus Biopharmaceuticals, Inc.
$0.05-3.77%
FNCHFinch Therapeutics Group, Inc.
$12.00-6.18%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$43.08-0.06%
TAT&T
$28.31+0.02%
RITMRithm Capital
$8.77-0.03%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.82+0.06%

Questions About MBXBF

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.